Nicole Baranda Balmaceda, MD

The AZUR-1 trial builds on earlier single-institution data showing that single-agent anti-PD-1 therapy could spare select patients with mismatch repair-deficient rectal cancer from surgery and radiation.

AMPLIFY-7P evaluated a lymph node-targeting mutant KRAS amphiphile vaccine versus observation as adjuvant therapy for patients with resected pancreatic ductal adenocarcinoma.

Additional analyses from the RASolute 302 trial offer further insight into daraxonrasib, a pan-RAS inhibitor, compared with chemotherapy in patients with previously treated metastatic pancreatic adenocarcinoma.

Practice-changing ESMO 2026 GI oncology highlights, including zanidatamab-based regimens that extend survival in HER2-positive gastroesophageal cancer, even in PD-L1–negative patients.